Calamos Advisors LLC Ligand Pharmaceuticals Inc Transaction History
Calamos Advisors LLC
- $14.5 Billion
- Q1 2024
A detailed history of Calamos Advisors LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Calamos Advisors LLC holds 9,035 shares of LGND stock, worth $761,289. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,035
Previous 4,586
97.01%
Holding current value
$761,289
Previous $327,000
101.83%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding LGND
# of Institutions
234Shares Held
16.5MCall Options Held
77.9KPut Options Held
25K-
Black Rock Inc. New York, NY2.87MShares$242 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$159 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C31.03MShares$87.1 Million0.09% of portfolio
-
Janus Henderson Group PLC London, X01.01MShares$85 Million0.04% of portfolio
-
Stephens Investment Management Group LLC697KShares$58.7 Million0.7% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $1.42B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...